A comprehensive systematic review and meta-analysis published in the Chinese Medical Journal demonstrates that pegylated interferon-alpha therapy significantly enhances the clearance of hepatitis B surface antigen in various populations with chronic hepatitis B virus infection. The study, conducted by Professor Enqiang Chen from West China Hospital and a team of researchers, provides critical evidence supporting personalized treatment strategies by evaluating treatment outcomes across different chronic infection groups. The findings were made available online on August 24, 2026, and address a significant gap in prior research, which had largely concentrated on single-dimensional analyses of specific subgroups rather than offering a comprehensive evaluation of the overall treatment population.
Chronic hepatitis B virus infection remains a major global public health challenge, particularly prevalent in endemic regions of Asia and sub-Saharan Africa. Achieving a functional cure is widely recognized as a key goal in managing this condition, as it can significantly reduce the risk of end-stage liver disease and improve patients’ quality of life. Hepatitis B surface antigen clearance or seroconversion serves as the primary indicator of this functional cure. However, spontaneous clearance of the antigen is rare, with an annual rate of only about 1% observed in both children and adults. Consequently, therapy based on pegylated interferon-alpha is currently regarded as one of the most promising options for attaining clinical cure, yet a holistic understanding of its efficacy across diverse patient groups was previously lacking.
To address this gap, the research team conducted the first comprehensive systematic review and meta-analysis summarizing hepatitis B surface antigen clearance and seroconversion rates. The analysis encompassed different chronic hepatitis B infections at various treatment durations and follow-up periods after therapy discontinuation. By aggregating data from a wide range of studies, the researchers aimed to elucidate the sources of variability in treatment outcomes. This approach allowed for a more nuanced understanding of how different patient characteristics and treatment protocols influence the likelihood of achieving antigen clearance, moving beyond the limitations of isolated subgroup analyses.
The meta-analysis revealed that pegylated interferon-alpha therapy achieves markedly higher clearance rates compared to spontaneous clearance or long-term nucleos(t)ide analog therapy. For instance, in inactive hepatitis B surface antigen carriers, the therapy achieves an antigen clearance rate of 57%, which stands in stark contrast to the 1.54% rate observed in patients on nucleos(t)ide analog monotherapy or untreated cohorts. In children with chronic hepatitis B, the treatment increases the clearance rate to 22%, a figure that is substantially higher than the spontaneous annual clearance rate of approximately 1% seen in untreated children. These findings highlight the superior efficacy of interferon-based therapy in specific patient populations.
Among nucleos(t)ide analog-treated chronic hepatitis B patients, the study found that individuals who were hepatitis B surface antigen-negative tended to exhibit higher clearance rates. Specifically, in patients with baseline antigen levels of 1500 IU/mL or lower, clearance rates could reach up to 35%, while those with levels below 1000 IU/mL saw rates as high as 45%. In contrast, the clearance rate associated with nucleos(t)ide analog monotherapy remains low, averaging approximately 0.22% per year, which amounts to only about 2.11% over a 10-year period.
The research team also conducted subgroup analyses focusing on Asian populations, which were predominantly Chinese, and other ethnic groups. Asian experts, who accounted for 72% of the included studies, have been pioneers in recognizing the significance of antigen clearance. Over nearly two decades of clinical experience, extensive research has been conducted on pegylated interferon-alpha across different infection populations. The rates of antigen clearance and seroconversion in Asian patients were found to be 21% and 18%, respectively.
Chronic hepatitis B is characterized by profound clinical heterogeneity, influenced by both viral and host immune factors. To elucidate the sources of this variability, the researchers performed a meta-regression analysis. This statistical approach revealed that heterogeneity was partially explained by treatment strategy, publication year, baseline hepatitis B e-antigen status, and study design. Clinically, these findings highlight that combining pegylated interferon-alpha with nucleos(t)ide analogs significantly improves the likelihood of achieving antigen clearance compared to interferon monotherapy.
Furthermore, the analysis identified specific predictors of favorable outcomes. Treatment duration beyond 48 weeks and a baseline hepatitis B e-antigen-negative status were found to be strong predictors of successful clearance. These factors provide a data-driven framework for precision hepatitis B management and patient stratification, allowing clinicians to tailor treatment plans based on individual patient characteristics.
Despite the promising results, the study acknowledges that the antigen clearance rate in treatment-naive chronic hepatitis B patients is around 5%, indicating that there is still room for improvement in treatment efficacy. Ongoing research is exploring broader treatment populations and optimizing strategies to further enhance clearance rates. These strategies include extending therapy duration, implementing intermittent dosing, and utilizing combination regimens involving novel agents.
Preliminary evidence suggests that combining new drugs with pegylated interferon-alpha could yield promising results, although confirmation of sustained high rates of clearance requires further investigation. Professor Chen concluded that pegylated interferon-alpha remains the cornerstone in pursuing a functional cure for hepatitis B, providing an opportunity for antigen clearance in different chronic infection groups. Personalized treatment is key to maximizing the benefits of this therapy and improving long-term outcomes for patients worldwide.
The study was supported by Clinical Novel Techniques of West China Hospital of Sichuan University, as noted in the funding information for the research. The findings were published in the Chinese Medical Journal, a peer-reviewed publication issued by the Chinese Medical Journals Publishing House Co., Ltd. The specific article, titled “Hepatitis B surface antigen clearance rate with pegylated interferon-α therapy in different chronic hepatitis B virus infection populations: A systematic review and meta-analysis,” was made available online on August 24, 2026.
Professor Enqiang Chen, the lead researcher, serves as a Chief Physician and Medical Team Leader in Infectious Diseases at West China Hospital. His professional background includes specialization in complex liver and infectious diseases, and he holds the position of a reserve candidate for the Sichuan Province Academic and Technical Leader. Chen’s academic contributions extend to editorial roles in several journals, including Current Stem Cell Research & Therapy, Journal of Clinical and Translational Hepatology, BMC Infectious Diseases, and World Journal of Virology. He has led five national and provincial research projects and has authored over 100 papers indexed in the Science Citation Index, in addition to co-editing more than 10 professional books.
Subject of Research: Efficacy of pegylated interferon-alpha for hepatitis B surface antigen clearance in chronic hepatitis B virus infection
Article Title: Chinese Medical Journal article review explores hepatitis B surface antigen clearance rate in chronic hepatitis B virus infection treated with pegylated interferon-α
Article References: Chinese Medical Journal article review explores hepatitis B surface antigen clearance rate in chronic hepatitis B virus infection treated with pegylated interferon-α. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: hepatitis B, pegylated interferon, HBsAg clearance, meta-analysis, chronic hepatitis B, functional cure, nucleos(t)ide analogs, clinical trial, viral infection, liver disease, Chinese, Medical
News Source: Kristina Jarvis. (November 13, 2026). Meta-analysis links pegylated interferon to higher hepatitis B clearance. Scienmag.



